CHIP WADOWSKI
New member
Maximus hrt case study begins next week...
MAXIMUS HRT will be enrolling participants to assess the effect of androgen replacement therapy on wellness and quality of life in men with late-onset hypogonadism
Treatment of late onset hypogonadism in men has been shown to relieve symptoms of sexual dysfunction and to improve body composition. However, the effect of treatment on wellness and quality of life, and cardiac risk factors has been less clear. We intend to evaluate the efficacy and side effects of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH). The study cohort comprises 50 male patients who are diagnosed prospectively with LOH and treated with testosterone replacement therapy (TRT) for at least 6 months through MAXIMUS Hormone Replacement Therapy (HRT). Our treatment protocol consists of parenteral bio-identical androgen replacement, adjuvant human chorionic gonaditropin (HCG), and aromatase inhibitor (AI) when indicated. Subjects are assessed prospectively using the SF-36 questionnaire. Study endpoints consist of wellness, quality of life, blood lipid profile, and adverse events. Fasting blood samples are analyzed for testosterone, estradiol, thyroid function profile, total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), ***947;-glutamyl transpeptidase (***947;-GTP), red blood cell count (RBC), hemoglobin (Hb), hematocrit (Ht), and prostate-specific antigen (PSA). Wellness and quality of life endpoints, as assessed using the validated SF-36, are expected to show significant short and long term improvements in the following sections: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health, after testosterone replacement therapy (TRT) (P < 0.05). Blood lipids are expected to improve (P<0.05). Adverse events are expected to be low.
MAXIMUS HRT will be enrolling participants to assess the effect of androgen replacement therapy on wellness and quality of life in men with late-onset hypogonadism
Treatment of late onset hypogonadism in men has been shown to relieve symptoms of sexual dysfunction and to improve body composition. However, the effect of treatment on wellness and quality of life, and cardiac risk factors has been less clear. We intend to evaluate the efficacy and side effects of testosterone replacement therapy (TRT) in men with late-onset hypogonadism (LOH). The study cohort comprises 50 male patients who are diagnosed prospectively with LOH and treated with testosterone replacement therapy (TRT) for at least 6 months through MAXIMUS Hormone Replacement Therapy (HRT). Our treatment protocol consists of parenteral bio-identical androgen replacement, adjuvant human chorionic gonaditropin (HCG), and aromatase inhibitor (AI) when indicated. Subjects are assessed prospectively using the SF-36 questionnaire. Study endpoints consist of wellness, quality of life, blood lipid profile, and adverse events. Fasting blood samples are analyzed for testosterone, estradiol, thyroid function profile, total cholesterol (TC), high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides (TG), aspartate aminotransferase (AST), alanine aminotransferase (ALT), ***947;-glutamyl transpeptidase (***947;-GTP), red blood cell count (RBC), hemoglobin (Hb), hematocrit (Ht), and prostate-specific antigen (PSA). Wellness and quality of life endpoints, as assessed using the validated SF-36, are expected to show significant short and long term improvements in the following sections: vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning, and mental health, after testosterone replacement therapy (TRT) (P < 0.05). Blood lipids are expected to improve (P<0.05). Adverse events are expected to be low.
